In assessing whether there is value in monitoring T3 levels and restoring them to normal in hypothyroidism, I think it helps to return to first principles. And no, “more T3 is better” is not a first principle.

In this next post in the T3 Controversies series, we cover whether T3 therapy must be used to account for tissues that can’t make their own T3.

In this first post of my “T3 Controversies” series, I address the claim that there are acquired forms of tissue resistance to thyroid hormone, which can be treated with high-dose T3 therapy.